Related by context. All words. (Click for frequent words.) 76 metastatic disease 73 metastases 71 metastatic prostate cancer 70 metastatic 68 tumor recurrence 68 tumors 68 glioblastoma 67 malignancy 67 malignancies 67 distant metastasis 67 metastatic breast cancer 67 neuroendocrine tumors 67 ovarian cancer 67 gastric cancer 66 melanoma 66 carcinoma 66 cancer 66 metastatic cancers 66 metastatic colon cancer 66 distant metastases 65 HER2 positive breast cancer 65 prostate adenocarcinoma 65 renal cell carcinoma 65 brain metastases 65 pancreatic adenocarcinoma 65 renal carcinoma 65 cancers 65 metastatic tumors 64 ovarian tumors 64 NSCLC 64 lung tumors 64 lymphoma 64 sarcoma 64 metastatic melanoma 64 Glioblastoma 64 prostate cancers 64 malignant melanoma 63 colorectal cancer 63 metastatic RCC 63 malignant growths 63 malignant pleural mesothelioma 63 ependymoma 63 metastasis 63 operable breast cancer 63 carcinoid cancer 63 pleural mesothelioma 63 angiosarcoma 63 bladder cancers 63 prostate cancer 63 gastrointestinal stromal tumor 63 tumor 63 GISTs 63 breast carcinoma 62 liver metastases 62 carcinoid 62 pancreatic cancers 62 synovial sarcoma 62 lung cancer 62 colon cancer 62 prostate cancer CaP 62 solid tumors 62 liver cancer 62 nasopharyngeal carcinoma 62 breast tumors 62 acute myelogenous leukemia AML 61 metastatic renal cell carcinoma 61 breast carcinomas 61 HER2 positive 61 Wilms tumor 61 Hodgkin Lymphoma 61 scleroderma 61 breast cancer 61 metastatic lung cancer 61 Glioblastoma Multiforme 61 astrocytoma 61 ADPKD 61 metastatic lesions 61 serous ovarian cancer 61 locoregional 61 gastrointestinal stromal tumor GIST 61 PCa 61 bone metastasis 61 medulloblastoma 61 glioblastomas 61 prostate cancer CRPC 61 fallopian tube carcinoma 61 ovarian cancers 61 follicular lymphoma 61 epithelial tumors 61 anaplastic 61 carcinoid tumors 61 lobular carcinoma 61 leiomyosarcoma 61 endometrial cancers 61 Cholangiocarcinoma 61 neuroblastoma 61 adenocarcinoma 60 melanomas 60 DIPG 60 peritoneal cancer 60 systemic scleroderma 60 malignant tumors 60 Metastatic breast cancer 60 bone metastases 60 cholangiocarcinoma 60 neoadjuvant therapy 60 epithelial ovarian 60 PCNSL 60 castration resistant prostate cancer 60 pancreatic cancer 60 neoplasia 60 multiple myeloma 60 acute myeloid leukemia 60 metastatic bladder 60 gastrointestinal stromal tumors 60 brain tumors 60 advanced NSCLC 60 thymoma 60 lymphocytic leukemia 60 breast cancers 60 carcinoid tumor 60 leukemia AML 60 hepatocellular carcinoma HCC 60 carcinomas 60 chronic lymphocytic leukemia 60 metastatic malignant melanoma 60 prostate cancer PCa 60 IV NSCLC 60 recurrent ovarian cancer 60 gastric cancers 59 micrometastases 59 Acute Leukemia 59 renal tumors 59 basal cell carcinoma BCC 59 curable cancers 59 recurrent NSCLC 59 HNSCC 59 pancreatic carcinoma 59 liver metastasis 59 GIST 59 metastatic gastric 59 neoplasm 59 differentiated thyroid 59 bladder cancer 59 squamous cell cancer 59 axillary dissection 59 lymphoblastic lymphoma 59 lymphomas 59 invasive carcinoma 59 alveolar rhabdomyosarcoma 59 nonmelanoma skin cancers 59 colorectal cancer CRC 59 metastatic colorectal cancer 59 paraganglioma 59 atypical hyperplasia 59 sarcomatoid 59 rhabdomyosarcoma 59 prostate carcinoma 59 leukemia 59 peritoneal carcinomatosis 59 soft tissue sarcomas 59 mesotheliomas 59 hepatocellular carcinoma 59 Hepatocellular Carcinoma HCC 59 seminoma 59 clinically localized prostate 59 thymic carcinoma 59 colorectal liver metastases 59 chemoradiotherapy 58 papillary thyroid cancer 58 relapsed ovarian cancer 58 squamous cell carcinoma SCC 58 Burkitt lymphoma 58 BRCA mutations 58 Metastatic melanoma 58 PNET 58 GIST tumors 58 neuroblastomas 58 recurrent glioblastoma multiforme 58 adenocarcinomas 58 grade gliomas 58 cisplatin chemotherapy 58 gastrointestinal cancers 58 osteosarcoma 58 mRCC 58 smoldering myeloma 58 disease 58 Metastatic 58 medullary thyroid cancer 58 biliary tract cancer 58 adenoid cystic carcinoma 58 Hodgkin Disease 58 Glioblastoma Multiforme GBM 58 node metastases 58 uveal melanoma 58 myeloproliferative diseases 58 Carcinoma 58 cervical carcinoma 58 HER2 positive metastatic breast 58 urothelial cancer 58 non Hodgkin lymphoma 58 osteosarcomas 58 epithelial ovarian cancer 58 leukemia ALL 58 mycosis fungoides 58 MALT lymphoma 58 Hurthle cell 58 CaP 58 CLL 58 endometrial cancer 58 testicular cancers 58 IV melanoma 58 lupus nephritis 58 lung metastases 58 lymph node metastases 58 neuroblastoma tumor 58 medulloblastomas 58 esophageal cancers 58 tumor progression 57 disease progression 57 lupus 57 nonsmall cell lung cancer 57 atherosclerotic disease 57 meningiomas 57 mucinous 57 pancreatic tumors 57 biochemical recurrence 57 stage IIIA 57 colorectal carcinoma 57 FSGS 57 brain tumor glioblastoma multiforme 57 unresectable 57 Wilm Tumor 57 malignant lesions 57 Acute myeloid leukemia 57 gastric adenocarcinoma 57 grade glioma 57 MYCN amplification 57 pituitary adenomas 57 lung metastasis 57 heavily pretreated 57 renal cell carcinomas 57 malignant lymphoma 57 Hurler syndrome 57 urothelial carcinoma 57 hematologic disorders 57 sarcomas 57 fibroadenomas 57 sporadic ALS 57 gastric atrophy 57 glioblastoma multiforme 57 neuroendocrine cancers 57 colorectal cancers 57 inoperable pancreatic cancer 57 oropharyngeal cancer 57 gliomas 57 squamous cell cancers 57 recurrent prostate cancer 57 benign polyps 57 CMV infection 57 acute leukemias 57 diffuse intrinsic pontine glioma 57 NF1 57 frontotemporal dementia 57 metastatic kidney 57 non Hodgkin Lymphoma 57 preoperative chemotherapy 57 embryonal rhabdomyosarcoma 57 chronic lymphocytic leukemia CLL 57 situ LCIS 57 premalignant 57 breast cancer recurrence 57 GBM tumors 57 Hodgkin lymphoma 57 Acute Myelogenous Leukemia 57 Testicular cancer 57 metastatic neuroendocrine tumors 57 basal cell carcinoma 57 ovarian carcinoma 57 precursor lesions 57 gastric carcinoma 57 Acute Myelogenous Leukemia AML 57 cisplatin resistant 57 Burkitt Lymphoma 57 squamous cell carcinoma 57 Mantle Cell Lymphoma 57 metastatic ovarian cancer 57 metastatic colorectal 57 cancerous tumors 57 malignant mesothelioma 57 EGFR inhibitors 57 lymph nodes 57 neoadjuvant chemotherapy 57 myelodysplastic syndrome MDS 57 cutaneous melanoma 57 anti angiogenic therapy 57 neuroendocrine carcinoma 57 Li Fraumeni Syndrome 57 familial ALS 56 pancreatic tumor 56 lymphatic tissue 56 tumor cells 56 sentinel node 56 pheochromocytoma 56 EGFR mutations 56 colorectal tumors 56 KRAS mutation 56 JMML 56 cell carcinoma 56 metastatic pancreatic cancer 56 invasive breast cancer 56 myeloma cells 56 AA amyloidosis 56 stage IIIB 56 neoplasms 56 glioblastoma multiforme GBM 56 Acute Lymphoblastic Leukemia 56 primitive neuroectodermal tumor 56 Adjuvant chemotherapy 56 metachronous 56 adenoma 56 Glioblastoma multiforme GBM 56 cystectomy 56 pT2 56 Sjögren syndrome 56 Wilms tumors 56 anthracyclines 56 myelodysplastic syndrome 56 lung cancers 56 ocular melanoma 56 esophageal cancer 56 liposarcoma 56 CMV disease 56 MGUS 56 chondrosarcoma 56 systemic lupus erythematosus 56 squamous cell lung cancer 56 premalignant lesions 56 squamous cell 56 retinoblastoma 56 Waldenstrom macroglobulinemia 56 Wegener granulomatosis 56 papillary carcinoma 56 basal cell cancers 56 gastrointestinal stromal tumors GIST 56 hepatocellular cancer 56 cell lung cancer 56 Barrett esophagus 56 refractory ovarian cancer 56 androgen deprivation 56 localized prostate cancer 56 medically inoperable 56 cancer metastasizes 56 myeloproliferative disorder 56 HER2 positive cancers 56 urothelial bladder cancer 56 Glioblastoma multiforme 56 resistant ovarian cancer 56 chemoradiation 56 resectable 56 HER2 overexpression 56 Osteosarcoma 56 superficial bladder cancer 56 platinum refractory 56 Sezary syndrome 56 choroidal melanoma 56 unresectable tumors 56 prostate tumors 56 papillary 56 lymphoblastic leukemia 56 nonmetastatic 56 neuro degenerative disease 56 myeloid leukemia 56 BRAF mutation 56 hormone receptor positive 56 oligodendrogliomas 56 lung fibrosis 56 prostate tumor 56 brain tumor 56 Myelodysplastic Syndrome 56 rectal cancers 56 lymph node metastasis 56 malignant neoplasm 56 PAOD 56 taxane therapy 55 cervical lesions 55 irinotecan chemotherapy 55 TACE 55 lobular cancer 55 idiopathic myelofibrosis 55 pancreatic 55 myeloma 55 myelofibrosis 55 membranous nephropathy 55 lymph node involvement 55 BRCA deficient 55 acute lymphoblastic leukemia 55 nodal metastasis 55 prostate cancer HRPC 55 pelvic lymph nodes 55 CD# mAb 55 acute myeloid leukemia AML 55 Non Hodgkin Lymphoma 55 papillary renal cell carcinoma 55 grade cervical intraepithelial 55 tumoral 55 invasive ductal 55 cervical lymph nodes 55 endometriosis 55 rectal cancer 55 colon cancers 55 Acute Lymphocytic Leukemia 55 diabetic nephropathy 55 non squamous NSCLC 55 Chronic lymphocytic leukemia 55 pre cancerous polyps 55 metastatic tumor 55 neurodegenerative disorder 55 metastatic GIST 55 chronic myelogenous leukemia CML 55 recurrent glioblastoma 55 Papillary 55 Endometrial cancer 55 sentinel lymph node biopsy 55 Alzheimers disease 55 LHRH receptor positive 55 angiogenesis inhibition 55 Follicular lymphoma 55 multidrug resistance 55 acute lymphocytic leukemia 55 allogeneic bone marrow 55 acute lymphoblastic 55 cutaneous squamous cell carcinoma 55 Rhabdomyosarcoma 55 APOL1 55 tyrosine kinase inhibitors 55 malignant transformation 55 non hodgkin lymphoma 55 autoimmune hemolytic anemia 55 pancreatic NET 55 malignant gliomas 55 myeloproliferative disorders 55 DCIS 55 Pleural mesothelioma 55 cytoreductive surgery 55 ovarian tumor 55 glioblastoma tumors 55 thyroid nodules 55 malignant pheochromocytoma 55 imatinib 55 PTLD 55 prostate cancer mCRPC 55 squamous 55 curative therapy 55 histological subtype 55 breast cancer metastasis 55 basal cell carcinomas 55 pulmonary metastases 55 Glioma 55 Malignant Melanoma 55 acute leukemia 55 nephritis 55 HER2 negative 55 neoplastic cells 55 chemotherapy 55 BRCA mutation carriers 55 oesophageal cancer 55 endometrial hyperplasia 55 gastroesophageal junction 55 metastatic malignant 55 neoplastic lesions 55 glioma cells 55 recurrent ovarian 55 lobular breast cancer 55 HCV infection 55 cardiotoxicity 55 paragangliomas 55 locoregional recurrence 55 idiopathic pulmonary fibrosis IPF 55 rectal carcinoma 55 invasive ductal carcinoma 55 nasopharyngeal carcinoma NPC 55 NMIBC 55 ependymomas 55 adjuvant radiation 55 histiocytosis 55 choriocarcinoma 55 colorectal cancer liver metastases 55 Hodgkin lymphoma HL 55 advanced adenomas 55 hypophosphatasia 55 contralateral breast 55 prognostic variables 55 imatinib Gleevec 55 precancerous cervical lesions 55 DLBCL 55 leukemia CLL 55 bladder carcinoma 55 trastuzumab 55 metastatic basal cell 55 EGFR mutation 55 cetuximab 55 skeletal metastases 55 soft tissue sarcoma 54 leukaemias 54 prostrate cancer 54 PSADT 54 recurrent glioblastoma multiforme GBM 54 glioblastoma GBM 54 tumors GIST 54 Multiple Myeloma 54 endometrial carcinoma 54 hormone refractory 54 hamartomas 54 Lymph node 54 juvenile myelomonocytic leukemia 54 molecular abnormalities 54 Ewing sarcoma 54 Gastric cancer 54 palliation 54 contralateral breast cancer 54 Follicular Lymphoma 54 pontine glioma 54 T1a 54 adjuvant radiotherapy 54 indolent lymphoma 54 biliary cancer 54 Chronic Lymphocytic Leukemia 54 Non Hodgkins Lymphoma 54 portal vein thrombosis 54 Malignant mesothelioma 54 degenerative disorder 54 Synovial sarcoma 54 ductal breast cancer 54 proliferative diabetic retinopathy 54 keloid 54 Gleevec resistant 54 bronchogenic carcinoma 54 lymph node 54 gefitinib Iressa 54 gastric lymphoma 54 micrometastasis 54 indolent lymphomas 54 Meningiomas 54 systemic lupus erythematosus SLE 54 Inflammatory Breast Cancer 54 Medulloblastoma 54 HNPCC 54 Metastases 54 Hashimoto thyroiditis 54 anthracycline taxane 54 pulmonary hypertension PH 54 essential thrombocythemia 54 atypia 54 activating mutations 54 Radical prostatectomy 54 liver fibrosis 54 breast lesions 54 histologically confirmed 54 adjuvant therapy 54 CLL cells 54 BRAF V#E mutation 54 EBRT 54 SCCHN 54 chemotherapy cisplatin 54 relapsing remitting multiple sclerosis 54 parathyroid 54 fibrosis 54 sorafenib 54 myeloproliferative neoplasms 54 biliary strictures 54 epithelial cancers 54 breast cancer subtypes 54 malignant neoplasms 54 pediatric malignancies 54 nodal metastases 54 Kaposi sarcoma 54 metastatic carcinoma 54 thyroid cancer 54 neoadjuvant treatment 54 retroperitoneal 54 KRAS wild 54 amyloidosis 54 pCR 54 tumor shrinkage 54 esophageal adenocarcinoma 54 tumor metastases 54 HER2 + 54 pT3 54 amyotrophic lateral sclerosis ALS 54 adenomas 54 cytoreduction 54 percutaneous biopsy 54 lymphatic cancer 54 prostate pancreatic 54 pancreatic neuroendocrine tumors 54 gynecological cancers 54 ductal carcinomas 54 nonmetastatic prostate cancer 54 K ras mutations 54 advanced adenoma 54 mutated KRAS 54 NF2 54 transitional cell carcinoma 54 melanoma lesions 54 oligodendroglioma 54 vulvodynia 54 acute GvHD 54 acute promyelocytic leukemia 54 esophageal tumors 54 bile duct cancers 54 Acute Myeloid Leukemia 54 gastrointestinal GI cancers 54 alkylating agents 54 acute myelogenous 54 Li Fraumeni syndrome 54 Smac mimetic 54 papillary thyroid carcinoma 54 seminomas 54 hemophagocytic lymphohistiocytosis 54 polycythemia vera 54 relapsing remitting 54 prostate cancer AIPC 54 relapsed leukemia 54 intestinal polyps 54 poorer prognosis 54 cancerous cells 54 SLNB 54 epithelioid 54 neuroendocrine cancer 54 diffuse gastric 54 uterine cancer 54 FLT3 54 precancerous condition 54 Merkel cell carcinoma 54 pancreatic islet cell 54 histopathologic examination 54 Anaplastic 54 occult metastases 54 prognostic indicator 54 postoperative pathology 54 hormonal therapies 54 WT1 54 metastatic adenocarcinoma 54 B CLL 54 malignant pancreatic 54 leukemias 54 dysplasia 54 intestinal metaplasia 54 unresectable stage 54 esophagogastric junction 53 tyrosine kinase inhibitors TKIs 53 Lymphoma 53 axillary lymph nodes 53 Crohn disease 53 antiangiogenic therapy 53 hyperoxaluria 53 diagnostic biomarker 53 hereditary breast cancer 53 Recurrences 53 mTOR inhibitors 53 adenomatous polyps 53 pleomorphic 53 multiple myeloma MM 53 radioiodine therapy 53 neuroblastoma tumors 53 malignant ascites 53 bladder tumors 53 Non Hodgkin lymphoma 53 malignant melanomas 53 cisplatin 53 papillary RCC 53 EGF receptor 53 ErbB2 positive 53 IDH1 mutation 53 CYT# potent vascular disrupting 53 p# mutations 53 leukemia APL 53 graft dysfunction 53 anticancer therapy 53 metastatic melanomas 53 renal transplantation 53 thoracic aortic disease 53 fungal meningitis 53 AA Amyloidosis 53 cancerdefine 53 vasculitis 53 colo rectal cancer 53 Androgen deprivation therapy 53 squamous cell carcinomas 53 Prognostic factors 53 chlorambucil 53 malignant cells 53 melanoma tumors 53 Adenocarcinoma 53 tumor subtypes 53 refractory CTCL 53 pancreatic lung 53 vinorelbine 53 Tumours 53 blastoma 53 de novo AML 53 inherited neurodegenerative disorder 53 prior chemotherapy regimens 53 estrogen receptor positive 53 Krabbe Disease 53 glioblastoma brain tumor 53 heavily pretreated patients 53 thyroid carcinoma 53 Acute Myeloid Leukaemia AML 53 IV metastatic melanoma 53 recurrences 53 Myelodysplastic syndrome 53 precancerous lesions 53 chronic myeloid 53 fibroadenoma 53 fibrotic disease 53 EBV infection 53 renal disease 53 ductal cancer 53 Metastasis 53 adenomatous 53 basal cell cancer 53 castrate resistant 53 radical nephrectomy 53 chemo resistant 53 systemic amyloidosis 53 rebleeding 53 panobinostat 53 cancerous lesions 53 imatinib resistance 53 metastatic NSCLC 53 carcinoids 53 cell lymphomas 53 castrate resistant prostate cancer 53 cranial irradiation 53 chronic GVHD 53 lesions 53 lymphoma CTCL 53 mycophenolate mofetil 53 ALCL 53 glioma 53 Peutz Jeghers syndrome 53 thrombotic complications 53 HER2 positivity 53 S. aureus infections 53 BCR ABL mutations 53 SHPT 53 cancerous polyps 53 myelofibrosis polycythemia vera 53 radiation therapy 53 Duchenne muscular dystrophy DMD 53 juvenile idiopathic arthritis 53 IV malignant melanoma 53 polycystic kidneys 53 oesophageal adenocarcinoma 53 esophageal carcinoma 53 Squamous 53 pilocytic astrocytomas 53 nonalcoholic steatohepatitis NASH 53 gefitinib 53 Gliomas 53 tumor histology 53 chronic granulomatous disease 53 lung carcinomas 53 hormone refractory prostate cancer 53 Acute Myeloid Leukemia AML 53 immunocompetent 53 Carcinoid tumors 53 Doxil ® 53 HBeAg negative 53 colorectal polyps 53 biochemical relapse 53 mutated KRAS gene 53 Li Fraumeni 53 recurrent colorectal cancer 53 Hodgkins Lymphoma 53 CIN2 + 53 hepatocellular carcinomas 53 curative resection 53 gynecologic cancers 53 transthyretin amyloidosis 53 hormone deprivation 53 pre cancerous lesions 53 interferon pathway 53 bile duct cancer 53 relapsed SCLC 53 bowel cancer 53 myelodysplastic syndromes MDS 53 postoperative delirium 53 cardiac dysfunction 53 Lou Gehrigs disease 53 grade dysplasia 53 intraperitoneal therapy 53 situ DCIS 53 chemoresistant 53 tuberous sclerosis complex 53 chemosensitivity 53 relapsed AML 53 HRPC 53 severe neutropenia 53 Gorlin syndrome 53 osteogenic sarcoma 53 liver resection 53 chronic HBV infection 53 metastatic renal cell 53 pre cancerous lesion 53 neurodegenerative disease 53 hepatoblastoma 53 Metastatic colorectal cancer 53 adjuvant chemotherapy 53 Leber Congenital Amaurosis LCA 53 keloids 53 indolent NHL 53 hepatic metastases 53 autologous transplants 53 imatinib resistant 53 Epstein Barr virus EBV 53 relapsing remitting MS 53 non squamous 53 depsipeptide 52 colorectal adenocarcinoma 52 Hodgkin lymphoma NHL 52 peritoneal mesothelioma 52 HER2 positive tumors 52 extracapsular extension 52 cilengitide 52 Aspergillus infections 52 TTR amyloidosis 52 relapsed GBM 52 leukemic cells 52 pelvic malignancies 52 primary immunodeficiencies 52 Langerhans cell histiocytosis 52 meningioma 52 estrogen receptor ER 52 haematological cancers 52 histologic subtype 52 bevacizumab Avastin ® 52 lymphoid 52 CIN3 52 benign tumors 52 cyclin E 52 supratentorial 52 Non Hodgkins lymphoma 52 diagnosed glioblastoma multiforme 52 leukaemic stem cells 52 geographic atrophy 52 cell carcinomas 52 Cutaneous T 52 dermatofibrosarcoma protuberans 52 cancerous polyp 52 haematopoietic 52 acute myelogenous leukemia 52 desmoplastic 52 ductal adenocarcinoma 52 sentinel nodes 52 Hodgkins Disease 52 neoplastic 52 Neuroblastoma 52 nutlin 3a 52 IGF 1R 52 familial pancreatic cancer 52 prognostic markers 52 tumor resection 52 vWD 52 beta thalassemia 52 cytotoxic chemotherapy 52 chemotherapy regimens 52 T1DM 52 prophylactic cranial irradiation 52 malignant ovarian 52 malignant cancerous 52 bowel cancers 52 situ CIS 52 leukemic stem cells 52 adrenocortical carcinoma 52 gynecological cancer 52 allogeneic stem cell 52 imatinib therapy 52 pre malignant lesions 52 orchiectomy 52 bortezomib 52 Basal cell carcinoma 52 CTEPH 52 recurrent GBM 52 malignant fibrous histiocytoma 52 T#I [002] 52 malignant brain 52 advanced unresectable 52 lymphoproliferative disorder 52 taxane chemotherapy 52 EGFR mutation positive 52 Acute lymphoblastic leukemia 52 SSc 52 autoantibodies 52 primary biliary cirrhosis 52 TP# mutation 52 myelogenous leukemia 52 aortic dissections 52 anaplastic astrocytoma 52 testicular cancer 52 underwent resection 52 cranial radiation 52 chemo radiotherapy 52 hematologic malignancies 52 dasatinib Sprycel 52 TNF antagonist 52 LQTS 52 lymphocytosis 52 esophagectomy 52 radical prostatectomy RP 52 ccRCC 52 Renal cell carcinoma 52 complement inhibitor eculizumab 52 interstitial pulmonary fibrosis 52 BRAF V#E 52 pulmonary metastasis 52 chemotherapeutic regimens 52 pancreatic cysts 52 endocrine tumors 52 TRAIL induced apoptosis 52 metastatic lymph nodes 52 temozolomide 52 neoplasias 52 embryonal 52 aortic rupture 52 myasthenia gravis MG 52 thyroid cancers 52 polyomavirus nephropathy 52 hepatorenal syndrome 52 von Willebrand disease 52 genomic alterations 52 stage IIIB IV 52 relapsing MS 52 GVHD 52 invasive candidiasis 52 hematopoietic cancers 52 fallopian tube cancers 52 prostate carcinomas 52 allogeneic transplants 52 anterior uveitis 52 small lymphocytic lymphoma 52 recurrent metastatic 52 colorectal adenoma 52 colorectal adenomas 52 resected 52 follicular thyroid cancer 52 metastatic lesion 52 HER2 52 hematopoietic cell 52 bleomycin 52 malignant 52 leukoencephalopathy 52 B Cell Lymphoma 52 malignant pleural mesothelioma MPM 52 gene amplification 52 Radiofrequency ablation 52 GBA mutations 52 tamoxifen therapy 52 pilocytic astrocytoma 52 Adjuvant therapy 52 Glioblastomas 52 1 diabetes T1D 52 lymphocytic 52 chemotherapy docetaxel 52 androgen independent 52 trastuzumab Herceptin ® 52 atypical rhabdoid tumor 52 ascites 52 Myelofibrosis 52 molecular subtypes 52 acute myeloid 52 axillary lymph node dissection 52 Bezielle 52 progressive neurodegenerative disorder 52 EGFR mutant 52 discoid lupus 52 DNA methylation patterns 52 proliferative disorders 52 cervical intraepithelial neoplasia 52 chemoresistance 52 oncoprotein 52 somatic mutations 52 metastatic bone 52 nodular melanoma 52 metastatic squamous cell carcinoma 52 interstitial pneumonia 52 allograft rejection 52 Cytoxan 52 chemoembolization 52 pheochromocytomas 52 primitive neuroectodermal tumors 52 normal karyotype 52 Basal cell 52 secondary hyperparathyroidism 52 HbF 52 MAb 52 anthracycline chemotherapy